Scarica l'app Stockscreener
50.56
3.14%
1.54
Dopo l'orario di chiusura:
50.63
0.07
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$49.02
Aprire:
$50.69
Volume 24 ore:
5.90M
Relative Volume:
1.26
Capitalizzazione di mercato:
$101.98B
Reddito:
$42.06B
Utile/perdita netta:
$7.96B
Rapporto P/E:
14.42
EPS:
3.5062
Flusso di cassa netto:
$5.64B
1 W Prestazione:
+2.56%
1M Prestazione:
+4.44%
6M Prestazione:
+32.43%
1 anno Prestazione:
+48.88%
Intervallo 1D:
$50.34
$51.46
Intervallo di 1 settimana:
$48.59
$51.46
Portata 52W:
$31.71
$51.46
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GSK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.56 | 98.88B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,064.04 | 932.17B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.79 | 492.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.93 | 389.14B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
142.27 | 264.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.87 | 266.67B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications - GlobeNewswire Inc.
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
A Look Into GSK Inc's Price Over Earnings - Sahm
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Sahm
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Finviz
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead - ts2.tech
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation - Insider Monkey
GSK (NYSE:GSK) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer - Finviz
Is GSK PLC Gaining or Losing Market Support? - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Best International Companies to Own: 2026 Edition - Morningstar
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating - ts2.tech
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts - ts2.tech
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
Analysts Offer Predictions for GSK's Q2 Earnings (NYSE:GSK) - MarketBeat
Quantbot Technologies LP Has $5.33 Million Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):